Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-15

Study Completion Date

2020-10-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

How safe and effective are CD34+ cell intracoronary injections for treating coronary endothelial dysfunction (CED)?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

NCT03508609

Coronary Microvascular Dysfunction

COMPLETED PHASE2

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

NCT04614467

Coronary Microvascular Dysfunction Coronary Microvascular Disease Microvascular Coronary Artery Disease

TERMINATED PHASE2

Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.

NCT05708547

Coronary Atherosclerosis

COMPLETED

Colchicine in Percutaneous Coronary Intervention

NCT02594111

Coronary Artery Disease Acute Coronary Syndrome

COMPLETED PHASE4

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

NCT02601560

Coronary Artery Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label, phase I study to determine safety and efficacy of CD34+ cells in the treatment and management of CED and early atherosclerosis. Coronary endothelial function will be assessed in all patients by the administration of intracoronary acetylcholine. Patients with endothelial dysfunction who meet study inclusion criteria will receive granulocyte cell stimulating factor (G-CSF), followed by apheresis. The mobilized peripheral cell product will be processed for selection of CD34+ stem cells, and the purified CD34+ cells will be administered intracoronary during cardiac catheterization. The patients will undergo repeat endothelial function assessment 6 months post-procedure, as well as clinical assessments as described below either via in-person assessment by a nurse or physician, or via phone-call using a standardized questionnaire at 1, 3, and 6 month follow-up visits. At one month, the patient will undergo basic laboratory testing including troponin levels, complete blood count (CBC), electrolyte panel, liver function testing and ECG. At 3 months, the patients will receive a phone follow-up by the study coordinator who will assess the patient for any clinical deterioration or significant worsening in symptoms. At 6 months, the patients will return for a clinical visit, which will include physical examination, basic laboratory testing and follow-up acetylcholine study with angiography to assess for change in endothelial function. The first three patients will be sequentially enrolled, and subsequent enrollment will be held until one month follow-up. Provided there are no safety concerns at this time, enrollment will continue.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis, Coronary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with Endothelial Dysfunction

Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.

Group Type EXPERIMENTAL

Autologous CD34+ Cells

Intervention Type DRUG

The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min

Granulocyte Colony-Stimulating Factor (G-CSF)

Intervention Type DRUG

5mg/kg twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous CD34+ Cells

The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min

Intervention Type DRUG

Granulocyte Colony-Stimulating Factor (G-CSF)

5mg/kg twice daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Neupogen Neulasta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of coronary endothelial dysfunction based on coronary angiogram and acetylcholine comprehensive coronary physiology study
* Able to provide informed written consent and willing to participate in all required study follow-up assessments

Exclusion Criteria

* Acute coronary syndrome or continuous/ongoing chest pain - unremitting and unresponsive to nitroglycerin or rest - persisting 4 or more days before stent placement. If the chest pain syndrome is transient and/or intermittent - even if it began more than 3 days prior to admission - the patient is not excluded.
* Subjects in cardiogenic shock (systolic pressure \< 80mm/Hg, on vasopressors or intraaortic counter pulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.
* Subjects unable to receive antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine,prasugrel, etc).
* Abnormal laboratory values (Hgb \<11 mg/dL; glomerular filtration rate (GFR)\<50; liver function tests (LFTs)\>2x upper limit of normal).
* Subjects receiving warfarin who have an international normalized ratio (INR) \>2 at the end of the screening phase or with major bleeding requiring active transfusion support.
* Subjects with severe cardiac valvular disease expected to undergo surgery within 1 year.
* Subjects with known severe immunodeficiency states (AIDS).
* Significant coronary artery disease on coronary angiogram
* Cirrhosis requiring active medical management.
* Malignancy requiring active treatment (except basal cell skin cancer).
* Subjects with documented active alcohol and /or other substance abuse.
* Females of child bearing potential unless a pregnancy test is negative within 7 days of the bone marrow harvest.
* Re-occlusion of the infarct related artery (IRA) prior to the infusion procedure.
* Planned revascularization intervention during the next 6 months. (A second PCI can be performed if done prior to qualifying cardiovascular magnetic resonance imaging (CMR) at least 96 hours post primary PCI).
* Participation in an ongoing investigational trial.
* Active or suspected bacterial infection requiring systemic intravenous antibiotics.
* Additional factors deemed unsuitable for trial enrollment per discretion of principal investigator
* Inmates

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No